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AbstrACt 
Introduction Low back pain (LBP) is the leading cause 
of disability worldwide, with prevalence doubling in the 
past 14 years. To date, prognostic screening tools display 
poor discrimination and offer no net benefit of screening 
over and above a ‘treat all’ approach. Characteristics 
of the primary sensory (S1) and motor (M1) cortices 
may predict the development of chronic LBP, yet the 
prognostic potential of these variables remains unknown. 
The Understanding persistent Pain Where it ResiDes 
(UPWaRD) study aims to determine whether sensorimotor 
cortex activity, an individual’s capacity for plasticity and 
psychosocial factors in the acute stage of pain, predict LBP 
outcome at 6 months. This paper describes the methods 
and analysis plan for the development of the prediction 
model.
Methods and analysis The study uses a multicentre 
prospective longitudinal cohort design with 6-month 
follow-up. 120 participants, aged 18 years or older, 
experiencing an acute episode of LBP (less than 6 weeks 
duration) will be included. Primary outcomes are pain and 
disability.
Ethics and dissemination Ethical approval has been 
obtained from Western Sydney University Human Research 
Ethics Committee (H10465) and from Neuroscience 
Research Australia (SSA: 16/002). Dissemination will 
occur through presentations at national and international 
conferences and publications in international peer-
reviewed journals.
trial registration number ACTRN12619000002189; Pre-
results.
IntroduCtIon
Low back pain (LBP) is the leading cause 
of disability worldwide, with prevalence 
doubling in the past 14 years.1 2 Twelve weeks 
after an acute episode of LBP, up to two-thirds 
of individuals continue to experience pain,3 
and the condition is defined as ‘chronic’ 
LBP.4 5 For some individuals, chronic LBP is 
self-limiting, but for others, chronic LBP is 
persistent, disabling and negatively impacts 
on daily life.6 Chronic LBP is resistant to treat-
ment, with current therapies failing to reduce 
the associated individual and socioeconomic 
burden.7 8 
There is increasing interest in the potential 
for stratified care approaches that enhance 
strengths and limitations of this study
 ► The Understanding persistent Pain Where it ResiDes 
(UPWaRD) study is the first adequately powered, 
longitudinal investigation of candidate predictors 
related to sensorimotor cortex activity and neuro-
plasticity in acute low back pain (LBP).
 ► The UPWaRD study includes assessment of both 
biological and psychosocial candidate predictor 
variables.
 ► Assessment of candidate predictors is performed 
using standardised, robust methodology.
 ► The statistical analysis plan and candidate predic-
tor variables are prespecified as recommended by 
the Prognosis Research Strategy framework and the 
Transparent Reporting of a multivariable prediction 
model for Individual Prognosis Or Diagnosis report-
ing guidelines for prognostic research.
 ► Although classification of recovery from LBP is de-
fined in this study based on cut-offs used in previous 
literature, there is no universal definition of recovery 
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the efficiency and benefits of health services.9–11 In 
chronic LBP, self-reported screening instruments that 
predominantly assess psychosocial variables such as 
the five-item instrument for ‘Predicting the Inception 
of Chronic Pain’ Tool (PICKUP)12; the nine-item The 
STarT Back Screening Tool13; and the short-form Orebro 
Musculoskeletal Pain Screening Questionnaire14 have 
discrimination performance values of 0.61, 0.69 and 
0.66, respectively (area under the curve [AUC]).15 An 
AUC statistic of <0.7 represents poor discrimination,16 
increasing the potential for misclassification of a large 
proportion of patients.12 Further analysis of these predic-
tion models using decision curve analysis suggests no net 
benefit of screening over and above a ‘treat all’ approach 
when considering the likelihood of poor outcome at 
4-month follow-up.15 Consequently, there is limited 
consensus regarding variables most likely to predict poor 
outcome following an episode of acute LBP.17
Emerging evidence suggests measures of brain structure 
and function may help identify individuals with subacute 
pain who are at risk of developing chronic pain.18 19 For 
example, altered activity in the primary sensory (S1) and 
motor (M1) cortices (‘maladaptive plasticity’) is hypoth-
esised to be associated with the development and main-
tenance of chronic pain.20 21 Data from cross-sectional 
studies demonstrate that people with chronic LBP have 
enlarged and shifted M1 representations of the back 
muscles that show greater overlap and have less discrete 
boundaries (termed ‘smudging’) compared with pain-
free individuals.22 23 Similarly, chronic LBP is associated 
with increased activity and a medial shift of the cortical 
representation of the back in S1 compared with healthy, 
pain-free individuals.24 Positive correlations exist between 
the magnitude of change in S1 and M1 activity and pain, 
functional impairment and symptom chronicity.22 24–27 
However, there have been no prognostic longitudinal 
studies of S1 and M1 activity in any pain condition and 
it is therefore not possible to determine whether these 
variables predict pain persistence following an episode of 
acute LBP.
One additional factor yet to be investigated within 
prognostic, longitudinal research in pain conditions is 
brain-derived neurotrophic factor (BDNF). BDNF acts 
as an important central modulator of neuroplasticity and 
is upregulated in response to activation of nociceptors 
during an acute pain episode.28 29 Further, carriers of 
the val66met allele of the BDNF gene exhibit a decreased 
capacity for neuroplasticity observed as a reduced poten-
tial for cortical reorganisation during motor learning.30–32 
No study has explored whether an individual’s capacity 
for neuroplasticity during an acute episode of LBP can 
predict LBP outcome.
Finally, evidence supports the capacity for psycho-
social factors to predict the development of chronic 
LBP.33 When psychosocial factors such as cognitive 
coping strategy and depression are assessed in prog-
nostic models, they explain ~26% of the total variance 
in 3-month LBP outcome.34–36 These figures suggest that 
although psychosocial factors contribute to the develop-
ment of chronic LBP, a large proportion of variation in 
outcome is due to factors that are currently unmeasured 
or unknown.37 38 The inclusion of both psychosocial and 
biological variables in prognostic models has the poten-
tial to predict a greater proportion of LBP outcome than 
psychosocial or biological variables in isolation.39
The UPWaRD (Understanding persistent Pain Where 
it ResiDes) study aims to determine whether S1 and M1 
activity, an individual’s capacity for plasticity and psycho-
social features assessed during an acute episode of LBP, 
predict 6-month LBP outcome. This study is the first 
adequately powered, longitudinal investigation of candi-
date predictors related to S1 and M1 activity and neuro-
plasticity in acute LBP. This protocol paper describes the 
method and analysis plan for the UPWaRD trial.
MEthods
design
This study uses a multicentre prospective longitudinal 
cohort design with 6-month follow-up of individuals 
experiencing an acute episode of LBP. The study is being 
carried out between December 2014 and June 2019 at two 
sites (Western Sydney University; Neuroscience Research 
Australia) in Sydney, Australia. Measures of candidate 
predictor variables are assessed within 6 weeks of acute 
LBP onset (T1) and the primary outcome measures (pain 
and disability) are assessed at 6-month follow-up (T2). 
Ethical approval has been obtained.
setting
Participants are recruited via: local hospitals in South East 
Sydney and South Western Sydney local health districts, 
New South Wales, Australia, primary care practitioners 
(eg, general practitioners and physiotherapists), news-
paper/online advertisements, flyers and social media 
sites such as Facebook.
Patient and public involvement
Patients and the public were not involved in the design 
of this protocol. Patient advocacy groups (Chronic Pain 
Australia, Pain Australia) will provide support for recruit-
ment through dissemination of recruitment flyers in 
newsletters, websites and social media. Individual test 
results will be provided to participants on request and a 
summary of the overall outcomes of the study will be avail-
able to all participants on completion of the trial.
Participants 
Potential participants are screened to determine whether 
they meet the following inclusion and exclusion criteria.
Inclusion criteria
Eligible participants must be 18 years or older and 
currently experiencing acute non-specific LBP—defined 
as pain in the region of the lower back, superiorly bound 
by the thoracolumbar junction and inferiorly by the 
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pain referred beyond this region that is not suspected 
radicular pain from neural tissue involvement. Pain must 
have been present for more than 24 hours and less than 
6 weeks duration following a period of at least 1-month 
pain-free.40–42 As we aim to determine which variables 
predict LBP outcome, regardless of whether this is the first 
episode of pain, participants need not be experiencing 
their first LBP episode. Previous history of LBP will be 
included as a candidate predictor in the statistical model. 
Participants must provide written informed consent to 
participate and be able to speak and read English.
Exclusion criteria
Known or suspected serious spinal pathology (fracture; 
malignancy, inflammatory or infective diseases of the 
spine; cauda equina syndrome or widespread neurolog-
ical disorder); suspected or confirmed pregnancy or less 
than 6 months post partum; suspected radicular pain 
(dominant leg pain, positive neural tissue provocation 
tests and/or any two of altered strength, reflexes, or sensa-
tion for the same nerve root, assessed clinically); previous 
lumbar spinal surgery (eg, spinal fusion, intervertebral 
disc replacement); presence of another painful condi-
tion (eg, fibromyalgia, neuropathy, rheumatoid arthritis); 
comorbidities affecting sensorimotor function or causing 
neurological deficit (eg, multiple sclerosis, spinal cord 
injury); history of psychological disorders requiring 
medication for symptom control (eg, major depressive 
disorder, bipolar disorder, schizophrenia) and/or contra-




Participants complete the Brief Pain Inventory (BPI) at T1 
and T244 where they are asked to score their pain inten-
sity on average over the previous week using an 11-point 
numerical rating scale (NRS: 0=‘no pain’, 10=‘worst 
pain imaginable’). At T2, NRS score ≤1 will be classified 
as recovered LBP and NRS score ≥2 will be classified as 




Participants complete the 24-point Roland Morris 
Disability Questionnaire (RMDQ) at T1 and T2.47 This 
questionnaire detects the level of disability experienced 
as a result of LBP. At T2, RMDQ score ≤6 will be classified 
as recovered LBP and RMDQ score ≥7 will be classified 
as chronic LBP. This definition of chronic LBP replicates 
the cut-off used in other prognostic tools.13 48
Candidate predictors
Fifteen candidate predictors are selected a priori based 
on a theoretical association with the development of 
chronic LBP (table 1).
sensory and anterior cingulate cortex activity
Sensory evoked potentials (SEPs) will be recorded in 
response to electrical stimulation of the paraspinal 
muscles24 through surface electrodes positioned 3 cm 
lateral to the L3 spinous process, ipsilateral to the side 
of worst LBP. The side of worst LBP is determined on 
the day of baseline testing by asking the participant ‘on 
average over the past 24 hours which side of your back is 
most painful’? If the participant is unable to determine 
the most painful side, and reports central LBP at all times 
over the past 24 hours, stimulation is applied ipsilateral 
to their dominant hand. Participants are seated comfort-
ably in a chair, with feet on the floor and arms relaxed. 
A constant current stimulator (Digitimer, DS7AH) 
delivers the non-noxious electrical stimuli through 
bipolar electrodes (silver-silver chloride disposable elec-
trodes; Noraxon USA, Arizona, USA) at 3 x an individ-
ual’s perceptual threshold. If this stimulus evokes pain, 
the intensity is reduced as required. Electrical stimuli are 
applied with a pulse duration of 1 ms and a frequency of 
2 Hz. A variable interval schedule of 20% is applied to 
reduce accommodation. Two blocks of 500 stimuli are 
recorded for each participant.49
S1 activity is recorded using electroencephalography 
(EEG) via gold-plated cup electrodes (Digitimer, Reus-
able Au and Ag EEG Cup Electrodes) positioned over S1 
(3 cm lateral and 2 cm posterior to Cz) on the side contra-
lateral to worst LBP and referenced to Fz according to 
the International 10/20 EEG placement system.50 EEG 
signals are amplified 50 000x, bandpass filtered between 
5 and 500 Hz and sampled at 1000 Hz using a Micro1401 
Table 1 A priori candidate predictors
Assessment domain Predictor variable
Sensory and anterior 
cingulate cortex activity
SEP N80 component area
SEP N150 component area
SEP P260 component area
Motor cortex activity L3 map volume
L5 map volume
L3/L5 centre of gravity overlap







Baseline pain intensity NRS score at T1
Previous history of low back pain
BDNF, brain-derived neurotrophic factor; DASS-21, 
Depression, Anxiety and Stress Scale; L3, electrode recording 
site 3 cm lateral to the L3 spinous process; L5, electrode 
recording site 1 cm lateral to the L5 spinous process; PCS, 
Pain Catastrophising Scale; PSEQ, Pain Self-Efficacy 
Questionnaire; SEP, sensory evoked potential; T1, within 


































pen: first published as 10.1136/bm





4 Jenkins LC, et al. BMJ Open 2019;9:e029027. doi:10.1136/bmjopen-2019-029027
Open access 
data acquisition system and Signal software (Cambridge 
Electronic Design [CED], Cambridge, UK). To exclude 
the potential interference of repeated sensory stimuli on 
motor cortical activity,49 SEPs are recorded after transcra-
nial magnetic stimulation (see below).
The area of the N80 component (between the first 
major downward deflection of the curve after stimulation 
and the first major negative peak, N80), N150 component 
(between the first negative peak, N80 and second nega-
tive peak, N150) and P260 component (between the second 
negative peak, N150 and the positive deflection of the 
curve starting around 150 ms after stimulus onset, P260) 
of the SEP are used in the analysis. The N80 component 
is thought to represent activity in S1, the N150 activity in 
the secondary sensory cortex (S2) and P260 activity in the 
anterior cingulate cortex.20 24 51
Motor cortex activity
Participants are seated comfortably in a chair, with their 
feet on the floor and arms relaxed. A tight fitting bathing 
cap is applied to each participants head, with the vertex 
determined using the 10/20 International EEG Electrode 
Placement system.52 Single-pulse, monophasic transcra-
nial magnetic stimulation (TMS) is delivered to the M1 
contralateral to the side of worst LBP (Magstim 200 stimu-
lator/7 cm figure-of-eight coil; Magstim Co., Dyfed, UK). 
During testing, the coil is positioned tangential to the 
skull and moved lateral to the midline. This orientation 
has been shown to minimise concurrent excitation of the 
opposite hemisphere and elicit consistent motor evoked 
potential (MEP) responses in paraspinal muscles.42 Using 
a stimulator intensity of 100%, with an interstimulus 
interval of ~5 s, five stimuli are delivered over premarked 
scalp sites on a 6×7 cm grid, commencing at the vertex.23
Surface electromyography (EMG) is recorded from 
the paraspinal muscles with electrodes (silver-silver chlo-
ride disposable electrodes; Noraxon USA, Arizona, USA) 
placed longitudinally at 1 cm lateral to the L5 spinous 
process, and 3 cm lateral to the L3 spinous process ipsi-
lateral to the side of worst LBP. These sites have been 
used previously38 and are appropriate for recording EMG 
from the back muscles.39 Ground electrodes are placed 
bilaterally over the anterior superior iliac spines. EMG 
data are preamplified 2000 times, bandpass filtered (20 
to 1000 Hz) and sampled at 2000 Hz using a Power 1401 
Data Acquisition System with Signal two software (CED, 
UK).
As paraspinal MEPs are difficult to elicit at rest,22 38–40 M1 
stimulation is conducted during submaximal paraspinal 
muscle contractions. Participants are asked to perform 
three maximum voluntary contractions (MVCs) of the 
paraspinal muscles against resistance for ~3 s. The target 
EMG amplitude is determined as 20% of the highest 
root mean square (RMS) EMG for 1 s from the average 
of the three MVCs. Target muscle activation is achieved 
by leaning backward into resistance provided from a 
pillow, while keeping the back straight. Visual and verbal 
feedback are provided to the participant throughout 
the procedure to ensure paraspinal muscle contraction 
remains at 20% of MVC during stimulation.
TMS map data are exported and analysed using 
MATLAB 7 (The MathWorks, USA). EMG traces of the 
five MEPs recorded at each scalp site are averaged. MEP 
onset and offset are visually identified from the aver-
aged traces and the RMS EMG amplitude between the 
onset and offset times calculated.22 23 53–55 Background 
RMS EMG between 55 and 5 ms prior to stimulation is 
subtracted.23
MEP responses are superimposed over the respective 
scalp sites to construct a topographical representation of 
the target paraspinal muscle and normalised to the peak 
response for each participant.27 Normalised values below 
25% of the peak response are removed and the remaining 
values rescaled between 0% and 100%.23
Two parameters are calculated from the normalised 
motor cortical maps. First, map volume, a measure of 
total excitability of the motor cortical representation, is 
calculated as the sum of the mean normalised RMS MEP 
at all active scalp sites. A scalp site is considered active 
if the normalised MEP response is equal to or greater 
than 25% of the peak response. Second, the centre 
of gravity, defined as the amplitude weighted centre 
of the map, is calculated for the motor cortical repre-
sentation of L3 and L5 paraspinal muscles using the 
formula:  CoG =
∑






Vi  where: 





Cheek swabs taken on the day of baseline testing are used 
to prepare genomic DNA (Isohelix DNA Isolation Kit). 
Samples taken at T1 are immediately frozen at −80°C and 
stored until analyses. Polymerase chain reaction (PCR) is 
performed to amplify a 197 bp product with the val66met 
polymorphism located at 73 bp, with reaction conditions 
of denaturation at 95°C for 2 min, 35 cycles of 95°C for 
15 s, 60°C for 15 s and 72°C for 30 s, with final extension at 
72°C for 5 min.58 Restriction digests are resolved on a 2% 
agarose gel. As the val66met polymorphism destroys the 
Eco721 site, the samples can be classified as VAL/VAL, 
VAL/MET or MET/MET based on the observed banding 
pattern. All samples are genotyped using two indepen-
dent PCRs.58
BDNF serum concentration
Peripheral venous blood is drawn into serum tubes (BD 
Vacutainer, SST II Advance) and clotted (30 min, room 
temperature) at T1. Serum is then separated by centrif-
ugation (2500 rpm, 15 min) and stored separately at 
−80°C until measurement. BDNF serum concentration 
is measured using ELISA (Simple Plex Cartridge Kit, 
Biotrend). All samples are measured in duplicate and aver-
aged for analysis. The detection limit is 62.5 pg/mL with 
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The Pain Catastrophising Scale (PCS) is included to assess 
catastrophising thoughts about pain. PCS includes 13 
items, scored on a five-point scale. A total score between 
0 and 52 is calculated, with higher scores indicating more 
severe catastrophic thoughts about pain.60
Depression, Anxiety and Stress Scale
A 21-item version of the Depression, Anxiety and Stress 
Scales Questionnaire (DASS-21) will be administered. 
The questionnaire includes three seven-item subscales: 
DASS-depression, DASS-anxiety, DASS-stress. A total score 
is obtained for the DASS-21 with higher scores indicating 
greater depression, anxiety and/or stress.61 62
Pain Self-Efficacy Questionnaire
The pain self-efficacy questionnaire consists of 10 items, 
each scored on a seven-point scale. The questionnaire 
evaluates the confidence of an individual in their ability 
to perform a range of functional activities while in pain. 
A total score between 0 and 60 is calculated, with higher 
scores representing greater self-efficacy beliefs.63
demographics and baseline pain intensity
Age and sex data will be collected from all participants 
at baseline. Baseline pain intensity will be drawn from 
the BPI administered at T1 (as described under primary 
outcome measures) where participants score their pain 
intensity on average over the previous week using the 
NRS.
statistical analysis
Data analysis will be carried out using SPSS for Windows 
(V.25; SPSS, Chicago, Illinois, USA). Continuous variables 
will be presented through centrality measures (mean, 
median), dispersion (SD and IQR) according to the 
distribution and categorical variables through frequen-
cies and percentages. A primary and secondary analysis 
will occur to interpret the collected data.
Primary analysis
The primary analysis will use multivariate linear regres-
sion models to determine the candidate predictors associ-
ated with (1) pain intensity (NRS: 0=‘no pain’, 10=‘worst 
pain imaginable’) and (2) disability at T2. Recovery from 
LBP is complex and highly individual47; there remains 
no clear consensus on what constitutes recovery from 
an episode of LBP. For this reason, we will first explore 
the data using a linear regression model that does not 
attempt to dichotomise outcomes into recovered/non-re-
covered. Maintaining continuous outcome variables also 
minimises information loss, increasing statistical power.
The cumulative probability of being recovered from an 
episode of LBP is reported to be 39.9% at 6 weeks, 58.2% at 
12 weeks and 72.5% at 12 months.64 These figures suggest 
data will be normally distributed. Therefore, we expect 
to analyse pain intensity and disability scores at T2 using 
linear regression, generalised linear models with normal 
distribution and identity link function. All predictors with 
a p value <0.20 in a univariate analysis will be considered 
for inclusion in the final linear regression multivariate 
model. Model assumptions will be tested, including a test 
of multicollinearity. Goodness of fit of the final linear 
regression model will be reported with adjusted R2 values. 
In the event that the data are overdispersed, we will opt 
for a Poisson or negative binomial model and log like-
lihood and Akaike’s information criterion (AIC) will be 
reported.
Secondary analysis
The secondary analysis will use logistic regression to 
investigate the relationship between baseline candidate 
predictors and measures of chronic LBP (pain intensity 
and disability). Logistic regression analysis will allow for 
development of a prognostic model in line with recom-
mendations of the Prognosis Research Strategy group 
and Transparent Reporting of a multivariable prediction 
model for Individual Prognosis Or Diagnosis (TRIPOD) 
statement.65 66 Further, the generated predicted proba-
bilities of recovery at T2 will allow for direct comparison 
with other published LBP prognostic tools.12–14 67–69
Variable selection
Multivariable logistic regression with backward stepwise 
selection will be employed. Backward stepwise selection is 
the preferred automated predictor selection technique, 
as correlations between predictors are considered in the 
modelling procedure.70 AIC will be used as a stopping 
rule for variable selection. Using AIC as a stop rule corre-
sponds to a significance level of α=0.157, is favourable in 
smaller data sets and accounts for model fit.70 71
Continuous predictor variables will be treated as linear 
in the primary analyses. As per the TRIPOD statement, 
categorisation of continuous variables is not necessary 
for statistical analysis and contributes to significant infor-
mation loss.70 The linearity of continuous predictor vari-
ables will be examined with the predicted probability 
of chronic LBP as the dependent variable using scatter 
plots and the Box-Tidwell transformation.72 A check for 
linearity will be performed and possible improvement of 
fit investigated by allowing some form of non-linearity.70 
For continuous predictor variables that demonstrate a 
significant non-linear relationship with the dependent 
variable, transformation will occur.
Model performance
We will examine the predictive performance of the 
prognostic models by analysing measures of calibration 
and discrimination. Calibration reflects the agreement 
between predictions from the model and observed 
outcomes, assessed graphically. The observed risk is 
plotted on the y-axis, against predicted risks on the 
x-axis. We will test for agreement between predicted 
and observed probabilities using the Hosmer-Leme-
show test.73 Discrimination refers to the ability of the 
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recover from LBP and those who will not. This will be 
reported using the concordance index, which equals the 
area under the receiver operating characteristic curve.74
sample size estimation
Primary analysis
Ten subjects will be ensured per variable (SPV) in the 
linear regression model to assess whether baseline vari-
ables are associated with pain intensity at T2. More than 
one-third of variables (>5 candidate predictors) are not 
anticipated to demonstrate a significant association 
during univariate analysis with the outcome of interest, 
or display multicollinearity, and will subsequently be 
excluded from the model. Thus, allowing for 20% loss 
to follow-up, with 10 remaining candidate predictors, we 
require 120 participants with acute LBP to ensure at least 
10 SPV.75
Secondary analysis
We will seek a minimum of five events per variable for 
logistic regression analysis.76 In line with the above sample 
size estimation for linear regression, we will recruit 120 
participants with acute LBP. Considering a maximum of 
10 candidate predictors remaining in the multivariable 
logistic regression model following backward stepwise 
selection, we require a minimum of 50 events (ie, presence 
of chronic LBP at T2). There is substantial variability in 
the clinical course of acute LBP with estimates for the risk 
of developing chronic LBP reportedly as high as 56%.77 
Further, recurrence of LBP is common, with 12-month 
recurrence rates reported in the literature ranging from 
24% to 80%.42 78 79 This variability suggests a sample size 
of 120 participants with acute LBP should be adequate to 
power the logistic regression analysis.
Missing data
Cases with missing values will be removed from the 
data set if follow-up rates are higher than 95%. If missing 
data exceed 5%, multiple imputation will be used in 
line with recommendations from the TRIPOD state-
ment.70 Multiple imputation involves creating multiple 
copies of the data set, with the missing values replaced by 
imputed values drawn from their predicted distribution 
in observed data.80 81 The number of imputations should 
be related to the fraction of missing data.82 We will report 
the methods used for combining all reported estimates 
following multiple imputation (ie, Rubin’s rules).70 83 
Where data are missing at random (ie, missing randomly, 
conditional on covariates), estimates based on multiple 
imputation are unbiased.84
EthICs And dIssEMInAtIon
Ethical approval has been obtained. Dissemination will 
occur through presentations at National and interna-
tional conferences and publications in international 
peer-reviewed journals.
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